Demand for Shingles Vaccine Surges as Patients Hope to Ward Off Dementia

Demand for the shingles vaccine has surged across British high street pharmacies as patients seek the shots in hopes of warding off dementia. While the vaccine is approved solely to prevent shingles—a painful rash caused by the reactivation of the chickenpox virus—high street chemists report that bookings have more than doubled over the past year. This trend follows a series of observational studies suggesting a potential link between the vaccine and a reduced risk of cognitive decline.

Key Clinical Takeaways:

• Bookings for the shingles vaccine have risen sharply across major pharmacies, driven in part by patients seeking potential protection against dementia.
• Recent observational studies, including research from Stanford University and the University of Oxford, suggest a potential 17% to 20% reduction in dementia risk following shingles vaccination.
• Public health bodies and researchers emphasize that while the correlation is promising, definitive proof of a direct cause-and-effect relationship between the vaccine and dementia prevention is not yet established.

Rising Demand at High Street Pharmacies

Recent figures from Boots show that bookings for its shingles vaccination service more than doubled over the past year, following a 30% increase in the previous year. A similar pattern emerged at Superdrug, where bookings rose by 41% year-on-year. While the vaccine is free for eligible groups on the National Health Service, adults under 65 typically pay approximately £450 for the full two-dose course. Patients seeking the shots cite both the physical toll of shingles and the growing body of research investigating cognitive health.

Varicella Zoster Virus May Contribute to Neurodegeneration

The surge in interest follows a flurry of academic research investigating whether the varicella zoster virus (VZV)—the pathogen responsible for both chickenpox and shingles—contributes to neurodegeneration. After a childhood chickenpox infection, the virus remains dormant in the nervous system. As the immune system weakens with age, the virus can reactivate, potentially driving inflammation, nerve cell stress, and the accumulation of amyloid and tau proteins associated with Alzheimer’s disease.

A study published in Nature last year by researchers at Stanford University utilized a natural experiment created by age-based eligibility cutoffs for the live-attenuated vaccine Zostavax in Wales. The Stanford team found that dementia rates were 8.5% lower over seven years in the vaccine-eligible group of women, an effect that translated to an estimated 20% reduction among those who actually received the shot. A subsequent 2024 study led by researchers at the University of Oxford analyzed health records for more than 200,000 US citizens, comparing the newer adjuvant-containing vaccine Shingrix with Zostavax. The Oxford team reported that dementia cases were 17% lower in those who received Shingrix, corresponding to an extra 164 days lived without the condition.

Researchers Stress Correlation Does Not Prove Causation

Despite these findings, researchers stress that existing studies demonstrate correlation rather than definitive causation.

Current Public Health Guidance

Meanwhile, epidemiologists and clinical researchers note that while the vaccine is safe and highly effective against shingles, its potential cognitive benefits remain an area of active investigation.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.